Cleveland Clinic Taussig Cancer Institute
G

Rationale and Early Results of Innate Immunity and Immune Check Point Blockade in the Treatment of MDS

By Cleveland Clinic Taussig Cancer Institute FEATURING Guillermo Garcia-Manero
By Cleveland Clinic Taussig Cancer Institute FEATURING Guillermo Garcia-Manero
108 views
December 12, 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
16:50
MDS Foundation

Pre-MDS States: How to Manage CHIP, CCUS and ICUS in the Clinic

Feat. M. Savona
29:20
MyCancerHaven

Experts Discuss Recent Advances in MDS

Feat. R. Vij, M. Sekeres
14:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "IMerge - Results From a Ph3 Study of Imet…

Feat. A. Zeidan
30:34
UChicago Medicine

2023 Updates in AML and MDS

Feat. O. Odenike
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
14:53
Talha Badar

DDX41 Mutated Germline Predisposition Syndrome-Associated Myeloid Ne…

33:37
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: MDS

Feat. G. Garcia-Manero
16:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Update on CHIP and CCUS

Feat. L. Weeks
07:56
MDS Foundation

Debates in HR-MDS: Cytoreduction Should Precede Allo-HCT

Feat. U. Platzbecker
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman